2012 Apr 5;119(14):3361-9. Our Aims. 208, no. 3, no. The Consortium aims to determine the mechanisms of virus-specific immunity and how these relate to clinical outcome in different patient groups. He is an NIHR Senior Investigator and was previously Chair of the Infection and Immunity Board at the Medical Research Council and the Clinical and Translational Research Committee at Cancer Research UK. 200.7k Followers, 1,052 Following, 3,018 Posts - See Instagram photos and videos from Kristin Gjelsvik (@kristingjelsvik) Professor Moss is also a member of the Scientific Advisory Board of Cell Medica. Professor Pam Kearns is leading the cancer arm of this study, and Professor Gordon Cook from Leeds will focus specifically on blood cancer. Targeting cancer’s vulnerabilities . 2013 Jan;13(1):45-55. Professor Moss is currently Chair of the Infections and Immunity Board at the Medical Research Council. 2012 Dec;159(5):589-98. Several of his discoveries have been taken into clinical trials. He studied Medical Sciences at the University of Cambridge and later on was a fellow of the Royal College of Pathologists. 734-743. https://doi.org/10.1182/bloodadvances.2018025502, Moss, P 2019, ''From immunosenescence to immune modulation': a re-appraisal of the role of cytomegalovirus as major regulator of human immune function', Medical Microbiology and Immunology, vol. Professor Paul Moss, UK-CIC lead and professor of haematology at the University of Birmingham, said the new data was "reassuring, potentially … 2012 Dec 20;30(36):4524-32. In this video Professor Moss describes his career to date, his passion for his research and how it is helping to change the world, and how he enjoys working with postgraduate researchers from the UK and abroad. 702-703. https://doi.org/10.1093/qjmed/hcaa195, Khakwani, M, Srinath, S, Pratt, G & Moss, P 2019, 'A rare complication of bone marrow aspiration and trephine biopsy: staphylococcus aureus osteomyelitis and septicaemia', British Journal of Haematology, vol. David Moss is the Paul Whiton Cherington Professor at Harvard Business School, where he teaches in the Business, Government, and the International Economy (BGIE) unit. Telehealth Ontario 2012 Nov 15;120(20):4246-55. Key areas such as understanding how immunity to COVID-19 is generated or … He earned his B.A. He also serves as a member of the Strategy Board at the MRC. 17, 14. https://doi.org/10.1186/s12979-020-00185-x, Wilkie, M, Satti, I, Minhinnick, A, Harris, S, Riste, M, Ramon, RL, Sheehan, S, Thomas, Z-RM, Wright, D, Stockdale, L, Hamidi, A, O'Shea, MK, Dwivedi, K, Behrens, HM, Davenne, T, Morton, J, Vermaak, S, Lawrie, A, Moss, P & McShane, H 2020, 'A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults', Vaccine, vol. Youngen. Professor Kenneth Boheler Department of Biomedical Engineering, Johns Hopkins University, USA . 2011 Dec 27;108(52):21176-81. Targeting cancer’s vulnerabilities . Clin Exp Immunol. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for chronic lymphocytic leukaemia. It has been going on for some months, and its impact is already being shared among professionals. oldest • newest. He leads a group of researchers at the University of Birmingham who are working to develop ways of harnessing the body’s own immune system to treat pancreatic cancer. David Moss is the Paul Whiton Cherington Professor at Harvard Business School, where he teaches in the Business, Government, and the International Economy (BGIE) unit. The programme will also investigate the maintenance of long-term immunity and inform the development of vaccines and new therapies. Paul also has a long-standing research interest in Cytomegalovirus (CMV), a herpesvirus that in healthy individuals is asymptomatic but can cause severe illness in immunocompromised transplant patients. Haematological malignancies; multiple myeloma; transplantation; leukemia; lymphoma; tumour antigens; tumour immunotherapy; testicular cancer; MHC tetramer; adoptive transfer; CMV; adoptive T cell therapy. Despite the curative potential of SCT for haematological malignancies, patients are at risk of mortality due to disease relapse, graft versus host disease (GvHD) and infection. He has been appointed as a member of the UoA1 panel (Clinical Medicine) in REF 2021. 10, 468. https://doi.org/10.3389/fimmu.2019.00468, Miles, DJC, Shumba, F, Pachnio, A, Begum, J, Corbett, EL, Heyderman, RS & Moss, P 2019, 'Early T cell differentiation with well-maintained function across the adult life course in sub-Saharan Africa', Journal of Immunology, vol. Tag: Professor Paul Moss. Find out more . The Medical Research Council’s Expert Group Workshop on ME/CFS Research took place on Thursday 19 November and Friday 20 November at Heythrop Park, Oxford. Professor Paul Moss is studying how pancreatic cancer cells find ways to stop our immune cells from finding and destroying them. 23, no. He earned his B.A. "But one can't translate this into protective immunity passports in any way. "The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection? Proc Natl Acad Sci U S A. Professor Moss is an honorary consultant at the University Hospitals Birmingham NHS Foundation Trust. Professor Paul Moss leads the scientific programme behind the study, which is funded by Leukaemia and Lymphoma Research. Professor Moss is also a member of the. In this role he oversees funding in basic, clinical and translational research applied to infectious human disease and to disorders of the human immune system. In collaboration with Professor Kilby, the team investigate the underlying mechanisms of immune homeostasis. In 1992-1993, he served as a senior economist at Abt Associates. Additional research is undertaken with Professor Stankovic on the genetics of Chronic Lymphocytic Leukaemia and with colleagues within UHBFT on research using Clinical Informatics.